Abstract

COMPARATIVE STUDY OF SAFETY AND EFFICACY OF DERIPHYLLIN, DOXOPHYLLINE AND ACEBROPHYLLINE IN PATIENTS WITH STABLE CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Alisha Elsa Simon*, Anju Anne Xavier, Jeenu C. Benoy, Deepthi Mathew, Dr. Midhun M., Department of Pulmonary Medicine, Dr. Santhosh M. Mathew

ABSTRACT

Chronic Obstructive Pulmonary Disease (COPD), defined by chronic inflammation and destruction of the airways and lung parenchyma is usually associated with tobacco smoking or prolonged exposure to other noxious particles and gases. Methyl Xanthines have been used in combination for bronchodilation in COPD since many years. Doxophylline, a novel methyl xanthine is claimed to be therapeutically similar but with better safety. This study was designed to compare the safety and efficacy of Deriphylline, Doxophylline and Acebrophylline at doses commonly used in patients with stable COPD. The study was conducted in the department of Pulmonary Medicine in a tertiary care hospital. 120 patients were divided into three groups. Patients taken were already on LABA, LAMA and steroid MDI. Group 1 was administered Deriphylline 150 mg twice a day. In group 2 Doxophylline 200 mg was given twice a day and group 3 was administered Acebrophylline 100 mg twice a day. Before and after the study period, patients were evaluated for improvement in the symptoms by using CAT score, PEFR, SpO2 and by six minute walk test. Medication adherence and adverse events were analysed by MMAS-8 and Naranjos Causality Assessment Scale respectively. The obtained parameters were analysed and the results concluded that patients taking doxophylline 200 mg showed significant improvement in the pulmonary functions followed by acebrophylline and deriphylline. It can be concluded that Doxophylline has better safety and efficacy than Deriphylline and Acebrophylline in patients with stable COPD.

Keywords: Methyl xanthines, Deriphylline, Doxophylline, Acebrophylline, Phosphodiesterase inhibitors.